Matrix metalloproteinase-2 (MMP-2 ) and-9 (MMP-9) gene variants and microvascular complications in type 2 diabetes patients
By:
References
- IDF Diabetes Atlas Ninth edition 2019.
- Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy: A Review. JAMA. 2015; 314: 2172–2181.
- Afkarian M, et al. Clinical Manifestations of Kidney Disease among US Adults with Diabetes, 1988-2014. JAMA. 2016; 316: 602–610.
- Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015; 2-17.
- Doria A. Genetics of Diabetes Complications. Curr Diab Rep. 2010; 10(6): 467–475.
- Negase H, Woessnsner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21494.
- Nikolaos P, Kadoglou, Daskalopoulou S, Perrera D, Liapis C. Matrix Metalloproteinases and Diabetic Vascular Complications. Angiology. 2005; 56: 173–189.
- Kowluru RA, Mishra M. Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy. Prog Mol Biol Transl Sci. 2017; 148: 67-85.
- Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med Overseas Ed. 2012; 366:1227-39.
- Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35: 556–564.
- Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376: 124–36.
- Diabetes Control and Complications Trial Research Group.The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995; 44: 968–983.
- Jerneld B, Algvere P. Relationship of duration and onset of diabetes to prevalence of diabetic r.tinopathy. Am. J. Ophtalmol. 1986; 102: 431–437.
- Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus UKPDS 69. Arch. Ophthalmol. 2004; 122(11): 1631–1640.
- Simó-Servat O, Hernández O, Simó R. Genetics in diabetic retinopathy: Current Concepts and New Insights. Curr Genomics. 2013; 14(5): 289–299.
- Giebel S, Menicucci G, Mc Guire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of blood – retinal barrier. Lab Invest. 2005; 85: 567-607.
- Mohammad G, Kowluru RA. Matrix metalloproteinase -2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest. 2010; 90(9): 1365-1372.
- Grant MB, Caballero S, Tarnuyyer RW, Bass KE, Ljubinkov AV, Spoerri PE, Galardy RE. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes. 1998; 47: 1311-7.
- Salzmann J, Limb GA, Khaw PT, Gregor Z, Webster L, Chignell AH, Charteris D. Matrix metalloproteinase and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophtalmo. 2000; 84: 1091-6.
- Singh K, Goyal P, Singh M, Deshmukh S, Upadhyay D, Kant S, Agrawal NK, Gupta SK, Singh K. Association of functional SNP-1562C>T in MMP-9 promoter with proliferative diabetic retinopathy in north Indian type 2 diabetes mellitus patients. J Diabetes Complications. 2017; 31(12): 1648-1651.
- Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2 ) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Molecular Visio. 2008; 14: 1114-1121.
- Singh R, Kishore L, Kaur N: Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014; 80: 21–35.
- Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006; 81(4): S3–11.
- Jann S, Bramerio MA, Beretta S, Koch S, Defanti CA, et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIPD. Neurology. 2003; 61: 1607-1610.
- Kuhad A, Singh P, Chopra K. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain. Expert Opin Ther Targets. 2015; 19(2): 177-85.
- Deng X, Ma P, Wu M, Liao H, Sung XJ. Role of matrix metalloproteinases in myelin abnormalities and mechanical allodynia in rodents with diabetic neuropathy. Aging Dis. 2021; 12(7): 1808-1820.
- Singh K, Agrawal NK, Gupta SK, Singh K. A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds. 2013; 12(3): 199-204.
- Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes care. 2014; 37: 2864-2883.
- United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2016.
- Maeda S, Haeda M, Guo B, et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 2001; 60: 1428-1434.
- Shalaby, K., Bahriz, R., Mahsoub, N. et al. Matrix metalloproteinase-9 gene polymorphism (-1562 C/T) and its correlation with diabetic nephropathy. Egypt J Intern Med. 2021; 33: 7.
- Feng S, Ye G, Bai S, Wei H, Liao X, Li L. Matrix Metalloproteinase-9 -1562C/T Gene Polymorphism Is Associated with Diabetic Nephropathy. Biomed Res Int. 2016; 1627143.
- Gantala SR, Kondapalli MS, Kummari R, Padala C, Tupurani MA, et al. Collagenase-1 (-1607 1G/2G), Gelatinase-A (-1306 C/T), Stromelysin-1 (-1171 5A/6A) functional promoter polymorphisms in risk prediction of type 2 diabetic nephropathy. Gene. 2018; 673: 22-31.
- Behrforouz A, Dastgheib SA, Abbasi H, Karimi-Zarrchi M, Javaheri A, Hadadan A, Tabatabaei RS, Meibodi B, Neamatzadeh H. Association of MMP-2, MMP-3 and MMP-9 polymorhisms with susceptibility to recurrent pregnancy loss. Fetal Pediatr Pathol. 2021; 40(5): 378-386.
- Sarray S, Dallel M, Lamine LBj Jairajpuri D, Sellami N et al. Association of matrix metalloproteinase-2 gene polymorphism with susceptibility to type 2 diabetesː A case control study. J Diabetes Complications. 2021; 35(6): 107908.
DOI: https://doi.org/10.2478/bjmg-2022-0001 | Journal eISSN: 2199-5761
Language: English
Page range: 35 - 40
Published on: Mar 1, 2023
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2023 Jelic M Andjelic, D Radojkovic, A Nikolic, Lj Rakicevic, T Babic, D Jelic, NM Lalic, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.